LIVE on April 23rd: Has Covid impacted India's long-term growth potential?
Here is the latest financial fact sheet of Aurobindo Pharma. For more details, see the Aurobindo Pharma quarterly results and Aurobindo Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
% ch | % | 0.6 |
No. of shares | m | 585.17 |
% ch week | % | 9.1 |
% ch 1-mth | % | 18.9 |
% ch 12-mth | % | 83.7 |
52 week H/L | Rs | 1,023.1/525.1 |
No. of Mths Year Ending |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
5-Yr Chart Click to enlarge
|
---|
AUROBINDO PHARMA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 1,280 | 1,541 | 895 | 809 | 830 | |
Low | Rs | 509 | 582 | 622 | 504 | 527 | |
Sales per share (Unadj.) | Rs | 415.1 | 235.8 | 254.6 | 281.6 | 333.9 | |
Earnings per share (Unadj.) | Rs | 54.0 | 34.6 | 39.3 | 41.4 | 40.4 | |
Diluted earnings per share | Rs | 26.9 | 34.6 | 39.3 | 41.4 | 40.4 | |
Cash flow per share (Unadj.) | Rs | 65.4 | 41.3 | 46.6 | 50.9 | 51.8 | |
Dividends per share (Unadj.) | Rs | 4.50 | 2.50 | 2.50 | 2.50 | 2.50 | |
Adj. dividends per share | Rs | 2.25 | 2.50 | 2.50 | 2.50 | 2.50 | |
Dividend yield (eoy) | % | 0.5 | 0.2 | 0.3 | 0.4 | 0.4 | |
Book value per share (Unadj.) | Rs | 184.5 | 124.5 | 160.0 | 199.4 | 237.1 | |
Adj. book value per share | Rs | 92.0 | 124.5 | 160.2 | 199.6 | 237.4 | |
Shares outstanding (eoy) | m | 291.98 | 585.17 | 585.88 | 585.88 | 585.91 | |
Bonus/Rights/Conversions | - | PREF | ESOP | - | ESOP | ||
Price / Sales ratio | x | 2.2 | 4.5 | 3.0 | 2.3 | 2.0 | |
Avg P/E ratio | x | 16.6 | 30.7 | 19.3 | 15.9 | 16.8 | |
P/CF ratio (eoy) | x | 13.7 | 25.7 | 16.3 | 12.9 | 13.1 | |
Price / Book Value ratio | x | 4.8 | 8.5 | 4.7 | 3.3 | 2.9 | |
Dividend payout | % | 8.3 | 7.2 | 6.4 | 6.0 | 6.2 | |
Avg Mkt Cap | Rs m | 261,147 | 621,041 | 444,390 | 384,630 | 397,569 | |
No. of employees | `000 | 11.6 | 13.3 | 14.0 | 17.3 | 17.9 | |
Total wages/salary | Rs m | 13,023 | 15,426 | 17,678 | 21,308 | 25,849 | |
Avg. sales/employee | Rs Th | 10,469.5 | 10,384.3 | 10,667.8 | 9,519.9 | 10,956.9 | |
Avg. wages/employee | Rs Th | 1,124.9 | 1,160.9 | 1,264.3 | 1,229.4 | 1,447.7 | |
Avg. net profit/employee | Rs Th | 1,361.1 | 1,522.9 | 1,645.8 | 1,397.9 | 1,324.3 |
AUROBINDO PHARMA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 121,205 | 137,986 | 149,157 | 164,998 | 195,636 | |
Other income | Rs m | 967 | 2,038 | 1,159 | 1,020 | 1,553 | |
Total revenues | Rs m | 122,172 | 140,024 | 150,316 | 166,018 | 197,189 | |
Gross profit | Rs m | 25,636 | 31,882 | 34,343 | 37,718 | 39,519 | |
Depreciation | Rs m | 3,326 | 3,924 | 4,276 | 5,580 | 6,680 | |
Interest | Rs m | 1,599 | 2,568 | 667 | 777 | 2,626 | |
Profit before tax | Rs m | 21,679 | 27,429 | 30,558 | 32,380 | 31,767 | |
Minority Interest | Rs m | 45 | 15 | 50 | 31 | 27 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | -881 | |
Tax | Rs m | 5,966 | 7,207 | 7,597 | 8,183 | 7,269 | |
Profit after tax | Rs m | 15,758 | 20,236 | 23,012 | 24,229 | 23,645 | |
Gross profit margin | % | 21.2 | 23.1 | 23.0 | 22.9 | 20.2 | |
Effective tax rate | % | 27.5 | 26.3 | 24.9 | 25.3 | 22.9 | |
Net profit margin | % | 13.0 | 14.7 | 15.4 | 14.7 | 12.1 |
AUROBINDO PHARMA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 83,794 | 102,944 | 92,062 | 121,878 | 153,645 | |
Current liabilities | Rs m | 60,814 | 78,402 | 66,056 | 86,659 | 120,429 | |
Net working cap to sales | % | 19.0 | 17.8 | 17.4 | 21.3 | 17.0 | |
Current ratio | x | 1.4 | 1.3 | 1.4 | 1.4 | 1.3 | |
Inventory Days | Days | 108 | 107 | 106 | 130 | 135 | |
Debtors Days | Days | 107 | 122 | 68 | 68 | 64 | |
Net fixed assets | Rs m | 39,218 | 50,278 | 62,919 | 83,345 | 103,909 | |
Share capital | Rs m | 292 | 585 | 586 | 586 | 586 | |
"Free" reserves | Rs m | 53,565 | 72,288 | 93,133 | 116,218 | 138,322 | |
Net worth | Rs m | 53,857 | 72,873 | 93,719 | 116,804 | 138,908 | |
Long term debt | Rs m | 13,111 | 7,428 | 1,814 | 4,512 | 1,800 | |
Total assets | Rs m | 128,124 | 159,202 | 162,494 | 211,052 | 264,544 | |
Interest coverage | x | 14.6 | 11.7 | 46.8 | 42.7 | 13.1 | |
Debt to equity ratio | x | 0.2 | 0.1 | 0 | 0 | 0 | |
Sales to assets ratio | x | 0.9 | 0.9 | 0.9 | 0.8 | 0.7 | |
Return on assets | % | 13.5 | 14.3 | 14.6 | 11.8 | 9.9 | |
Return on equity | % | 29.3 | 27.8 | 24.6 | 20.7 | 17.0 | |
Return on capital | % | 34.8 | 37.4 | 32.7 | 27.4 | 23.8 | |
Exports to sales | % | 51.6 | 51.4 | 50.8 | 48.9 | 49.6 | |
Imports to sales | % | 19.2 | 19.0 | 18.2 | 19.3 | 18.8 | |
Exports (fob) | Rs m | 62,514 | 70,927 | 75,761 | 80,681 | 97,091 | |
Imports (cif) | Rs m | 23,272 | 26,193 | 27,089 | 31,853 | 36,741 | |
Fx inflow | Rs m | 62,613 | 71,015 | 75,838 | 80,727 | 97,316 | |
Fx outflow | Rs m | 25,329 | 28,799 | 30,224 | 34,700 | 40,589 | |
Net fx | Rs m | 37,284 | 42,216 | 45,613 | 46,027 | 56,727 |
AUROBINDO PHARMA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 12,368 | 14,198 | 32,786 | 19,545 | 16,220 | |
From Investments | Rs m | -13,980 | -14,452 | -17,870 | -19,266 | -28,768 | |
From Financial Activity | Rs m | 932 | 3,654 | -19,153 | 8,642 | 19,191 | |
Net Cashflow | Rs m | -680 | 3,397 | -4,239 | 8,919 | 6,656 |
Share Holding
|
Company Information
|
CHM: K. Ragunathan | COMP SEC: A. Mohan Rami Reddy | YEAR OF INC: 1986 | BSE CODE: 524804 | FV (Rs): 1 | DIV YIELD (%): 0.3 |
Read: AUROBINDO PHARMA 2018-19 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: PIRAMAL ENTERPRISES NOVARTIS GLENMARK PHARMA SUN PHARMA NEULAND LABS
Compare AUROBINDO PHARMA With: PIRAMAL ENTERPRISES NOVARTIS GLENMARK PHARMA SUN PHARMA NEULAND LABS
Compare AUROBINDO PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets recouped early losses during afternoon deals and ended today's volatile session higher.
For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
In this video I tell you the three Nifty ETFs I think are the best.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
There is no stopping this 11-bagger stock from significant upside.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
More